Recent updates on biological activities of oxadiazoles

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1027-1046

  Saha, Rikta ^a   Tanwar, Omprakash ^a   Marella, Akranth ^a   Alam, M Mumtaz ^a   Akhter, Mymoona ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Biological activities; Five membered heterocyclic ring; Oxadiazole

Indexed keywords

1 [2[5 (1 BENZENESULFONYL PROPYL) [1, 3, 4] OXADIAZOL 2 YL SULFANYL] ETHYL] 4 (2 METHOXY PHENYL) PIPERAZINE; 1, 3, 4 OXADIAZOLE DERIVATIVE; 2 METHYL 1, 3, 4 OXADIAZOL 5 YL; 2, 5 DISUBSTITUTED 1, 3, 4 OXADIAZOLE DERIVATIVE; 3 (2 FURANYL) 5 (4 CHLORO 3 ISOTHIOCYANATOPHENYL) L,2,4 OXADIAZOLE; 3 (2 FURANYL) 5 (4 ISOTHIOCYANATOPHENYL) L,2,4 OXADIAZOLE; 3 (4 ISOTHIOCYANATOPHENYL) 1,2,4 OXADIAZOLE; 3, 3 DIPHENYL3 (2 ALKYL L, 3, 4 OXADIAZOL 5 YL) PROPYLCYCLOALKYLAMINE; 3, 5 (ISOTHIOCYANATOPHENYL) L,2, 4 OXADIAZOLE; 4 PHENYL 1, 2, 5 OXADIAZOLE 3 CARBONITRILE 2 OXIDE; 5 (2 CHLORO 4 ISOTHIOCYANATOPHENYL) 3 (2 FURYL) 1,2,4 OXADIAZOLE; 5 (HETEROCYCLES) 3 (ISOTHIOCYANOPHENYL) OXADIAZOLE DERIVATIVE; 5 AMINO 3 [2 (5 NITRO 2 FURYL) 5 AMINO 3 [2 (5 NITRO 2 FURYL); 5 METHYL 3 PHENYL 1, 2, 4 OXADIAZOLE; ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT; ANTISCHISTOSOMAL AGENT; ISONIAZID; LC 150444; N [3 PHENYL1, 2, 4 OXADIAZOL 5 YL METHYL] PHTHALIMIDE; OFLOXACIN; OXADIAZOL 2 ONE DERIVATIVE; OXADIAZOLE DERIVATIVE; PHOSPHODIESTERASE IV; QUINAZOLINE 4 ONE WITH 1, 3, 4 OXADIAZOLE DERIVATIVE; TRIPTAN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREASE;

ANALGESIC ACTIVITY; ANTHELMINTIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIDIARRHEAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BACTERIAL STRAIN; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CYTOTOXICITY; ENZYME INHIBITION; EPILEPSY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYDROPHILICITY; HYPOGLYCEMIA; INFLAMMATION; MIGRAINE; MOLECULAR DOCKING; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; REVIEW; SCHISTOSOMIASIS;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR STRUCTURE; OXADIAZOLES;

EID: 84878644123     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313070007     Document Type: Review

References (142)

1. Gupta, R. R.; Kumar, M.; Gupta, V. Heterocyclic Chemistry, vol II.; Springer Verlag: Germany, 1999.
2. Wang, Y.; Sauer, D. R.; Djuric, S. W. A simple and efficient one step synthesis of 1,3,4-oxadiazoles utilizing polymer-supported reagents and microwave heating. Tetrahedron Lett., 2006, 47, 105-108.
3. Brown, P.; Best, D. J.; Broom, N. J. P.; Cassels, R.; O'Hanlon, P. J.; Mitchell, T. J.; Osborne, N. F.; Wilson, J. M. The Chemistry of Pseudomonic Acid, Heterocyclic Replacement of the a,P-Unsaturated Ester: Synthesis, Molecular Modeling, and Antibacterial Activity. J. Med. Chem., 1997, 40, 2563-2570.
4. Vasilev, N. V.; Romanov, D. V.; Bazhenov, A. A.; Lyssenko, K. A.; Zatonsky, G. V. Intramolecular cycloaddition of fluorinated 1,3,4-oxadiazoles to dienes. J. Fluorine Chem., 2007, 128, 740-747
5. Ohmoto, K.; Yamamoto, T.; Horiuchi, T.; Imanishi, H.; Odagaki, Y.; Kawabata, K.; Sekioka, T.; Hirota, Y.; Matsuoka, S.; Nakai, H.; Toda, M.; Cheronis, J. C; Spruce, L. W.; Gyorkos, A.; Wieczorek, M. Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. J. Med. Chem., 2000, 43, 4927-4929.
6. Meanwell, N. A. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem., 2011, 54, 2529-2591.
7. Gilani, S. J.; Khan, S. A.; Siddiqui N. Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid. Bioorg. Med. Chem. Lett., 2010, 20, 4762-4765.
8. Adelstein, G. W.; Yen, Ch. H.; Dajani, E. Z.; Bianchi, R. G. 3,3-Diphenyl-3-(2-alkyl-l,3,4-oxadiazol-5-yl)propylcycloalkylaminaes, a Novel Series of Antidiarrheal Agents. J. Med. Chem., 1976, 19, 1221-1225.
9. Swain, C. J.; Baker, R.; Kneen, C; Moseley, J.; Saunders, J.; Seward, E. M.; Stevenson, G.; Beer, M.; Stanton, J.; Watling, K. Novel 5-HT3 Antagonists. Indole Oxadiazoles. J. Med. Chem., 1991, 34, 140-151.
10. Budzik, B., Garzya, V.; Shi, D.; Walker, G.; Lauchart, Y.; Lucas, A. J.; Rivero, R. A.; Langmead, C. J.; Watson, J.; Wu, Z.; Forbes, I. T.; Jin, J. 2'Biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling. Bioorg. Med. Chem. Lett., 2010, 20, 3545-3549.
11. Sayed, A. A.; Simeonov, A.; Thomas, C. J.; Inglese, J.; Austin, C. P.; Williams, D. L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med., 2008, 14, 407-412.
12. Warmus, J. S.; Flamme, C; Zhang, L. Y.; Barrrett, S.; Bridges, A.; Kaufman, M.; Tecle, H.; Gowan, R.; Sebolt-Leopold, J.; Leopold, W.; Merriman, R.; Przybranowski, S.; Valik, H.; Chen, J.; Ohren, J.; Pavlovsky, A.; Whithead, C; Ahang, E. 2-Alkylamino-and alkoxysubstituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase). Bioorg. Med. Chem. Lett., 2008, 18, 6171-6174.
13. McBriar, M. D.; Clader, J. W.; Chu, I.; Del Vecchio, R. A.; Favreau, L.; Greenlee, W. J.; Hyde, L. A.; Nomeir, A. A.; Parker, E. M.; Pissarnitski, D. A.; Song, L.; Zhang, L.; Zhao, Z. Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active y-secretase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 215-219.
14. Bhatia, S.; Gupta, M. 1, 3, 4-Oxadiazole as antimicrobial agents: An overview. J. Chem. Pharm. Res., 2011, 3(3), 137-147.
15. Nagaraj Chaluvaraju, K.C.; Niranjan, M.S.; Kiran S. 1, 3, 4 Oxadiazole: A Potent Drug Candidate with Various Pharmacological Activities. Int. J. Pharm. Sci., 2011, 3(3), 9-16.
16. Yu, J.; Zhang, S.; Li, Z.; Lud, W.; Cai, M. Stereoselective synthesis, structural characterization, and properties of 1,2-O-isopropylidene-3-C-(5-phenyl-1,2,4-oxadiazol-3-yl)-P-D-psicopyranose. Bioorg. Med. Chem., 2005, 13, 353-361.
17. Anjos, J. V. D.; Sinou, D.; Meloc, S. J. d.; Srivastava, R. M. Synthesis of glycosyl-triazole linked 1,2,4-oxadiazoles. Carbohydrate Research, 2007, 342, 2440-2449.
18. Anjos, J. V. d.; Ricardo Filho, A.W. N.; Nascimento, S. C. d.; Srivastava, R. M.; Melo, S. J. d.; Sinou, D. Synthesis and cytotoxic profile of glycosyl-triazole linked to 1,2,4-oxadiazole moiety at C-5 through a straight-chain carbon and oxygen atoms. Eur. J. Med. Chem., 2009, 44, 3571-3576.
19. Tóth, M.; Kun, Sándor E. B.; Benltifa, M.; Tallec, G.; Vidal, S.; Docsa, T.; Gergely, P.; Somsák, L.; Praly, J. P. Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase. Bioorg. Med. Chem., 2009, 17, 4773-4785.
20. Dalvie, D. K.; Kalgutkar, A. S.; Khojasteh-Bakht, S. C; Obach, R S.; O'Donnell, J. P. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol, 2002, 15(3), 269-299.
21. Hawkins, D. R. Biotransformations: A survey of the biotransformations of drugs and chemicals in animals. vol 7.; The Royal Society of Chemistry: Cambridge, 1996.
22. Cerecetto, H.; Dias, E.; Di Maio, R.; González, M.; Pacce, S.; Saenz, P.; Seoane, G.; Suescun, L.; Mombrú, A.; Fernández, G.; Lema, M.; Villalba, J. Synthesis and Herbicidal Activity of N-Oxide Derivatives. J. Agric. Food Chem., 2000, 48, 2995- 3002.
23. Ling, Y.; Ye, X.; Ji, H.; Zhang, Y.; Lai, Y.; Peng, S.; Tian, J. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents Bioorg. Med. Chem., 2010, 18, 3448-3456.
24. Carvalho, P. S. d.; Maróstica, M.; Gambero, A.; Pedrazzoli Jr J. Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety. Eur. J. Med. Chem., 2010, 45, 2489-2493.
25. Aguirre, G.; Boiani, L.; Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Porcal, W.; Denicola, A.; Moller, M.; Thomson, L.; Tortora, V. Benzo[1,2-c]1,2,5-oxadiazole N-oxide derivatives as potential antitrypanosomal drugs. Part 3: Substituents-clustering methodology in the search for new active compounds. Bioorg. Med. Chem., 2005, 13, 6324-6335.
26. Summa, V.; Petrocchi, A.; Bonelli, F.; Crescenzi, B.; Donghi, M.; Ferrara, M.; Fiore, F.; Gardelli, C; Gonzalez Paz, O.; Hazuda, D.J.; Jones, P.; Kinzel, O.; Laufer, R.; Monteagudo, E.; Muraglia, E.; Nizi, E.; Orvieto, F.; Pace, P.; Pescatore, G.; Scarpelli, R.; Stillmock, K.; Witmer, M. V.; Rowley, M. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV/AIDS infection. J. Med. Chem., 2008, 51, 5843-5855.
27. Erik, S.; Srinivas O.; Kavya, R.; and Neamati, N.; Raltegravir, elvitegravir, and metoogravir: the birth of "me-too"HIV-1 integrase inhibitors. Retrovirology, 2009, 6-25.
28. Jones, A. M.; Helm, J. M. Emerging treatments in cystic fibrosis. Drugs, 2009, 69, 1903-1910.
29. James, N. D.; Growcott, J. W. Zibotentan. Drugs Future, 2009, 34, 624-633.
30. Lim, K. S.; Cho, J. Y.; Kim, B.H.; Kim, J. R.; Kim, H. S.; Kim, D. K.; Kim, S. H.; Yim, H J.; Lee, S. H.; Shin, S. G.; Jang, I. J.; Yu, K. S. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br. J. Clin. Pharmacol, 2009, 68(6), 883-890.
31. Saini, R.; Rai, A. K.; Kesari, A. N.; Shaharyar, M. Synthesis and Biological Evaluation of 2, 5 Di-substituted 1, 3, 4 oxadiazoles. Asian J. Res. Chem., 2009, 2(1), 34-36.
32. Ravindra, K. C; Vagdevi, H. M.; Vaidya, V. P.; Padmashali, B. Synthesis, antimicrobial, and anti-inflammatory activities of 1,3,4-oxadiazoles linked to naphtha[2,1-b]furan. Ind. J. Chem., 2006, 45B, 2506-2511.
33. Donawade, D. S.; Raghu, A. V.; Gadaginamath, G. S. Synthesis and antimicrobial activity of new 1-substituted-3-pyrrolyl aminocarbonyl/oxadiazolyl/triazolyl/5-methoxy-2-methylindoles and benz[y]indoles. Ind. J. chem., 2006, 45B, 689-696.
34. Mashelkar, U. C; Audi, A. A. Synthesis of some novel 4-substituted coumarins having potential biological activity. Ind. J. Chem., 2006, 45B, 2506-2511.
35. Mulwad, V. V.; Chaskar, A. C. Synthesis and antibacterial activity of new oxadiazolo[1,3,5]-triazine, 1,2,4-triazolo and thiadiazolo 1,3,4-oxadiazole derivatives. Ind. J Chem., 2006, 45B, 1710-1715.
36. Mogilaiah, K.; Vidya, K. Synthesis and antibacterial activity of 1,3,4-oxadiazolyl-1,8-naphthypyridines. Ind. J. Chem., 2006, 45B, 1905-1908.
37. Desai, N. C; Bhavsar, A. M.; Shah, M. D.; Saxena, A. K. Synthesis and QSAR studies of thiosemicarbazide 1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles derivatives as potential antibacterial agents. Ind. J. Chem., 2008, 47B, 579-589.
38. Narayana, B.; Ashalatha, B. V.; Raj, K. K. V.; Sarojini B. K. Synthesis and studies on antimicrobial, antiinflammatory and antiproliferative activities of heterocycles derived from 4-/5-/6-/7-nitro/5-fluoro/chloro/bromoindole-2-carbohydrazides. Ind. J. Chem., 2009, 48B, 1794-1805.
39. El-Emam, A. A.; Al-Deeb, O. A.; Al-Omara, M.; Lehmann, J. Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1- adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1- adamantyl)-3-substitutedaminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem., 2004, 12, 5107-5113.
40. Somani, R. R.; Shirodkar, P. Y. Oxadiazole: A biologically important heterocycle. Der Pharma Chemica., 2009, 1. 130-140.
41. Mamolo, M. G.; Zampieri, D.; Vio, L.; Fermeglia, M.; Ferrone, M.; Pricl, S.; Scialino, G.; Banfi, E. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations. Bioorg. Med. Chem., 2005, 13, 3797-3809.
42. Macaev, F.; Rusu, G.; Pogrebnoi, S.; Gudima, A.; Stingaci, E.; Vlad, L.; Shvets, N.; Kandemirli, F.; Dimogloa, A.; Reynolds, R. Synthesis of novel 5-aryl-2-thio-1,3,4-oxadiazoles and the study of their structure-anti-mycobacterial activities. Bioorg. Med. Chem. 2005, 13, 4842-4850.
43. Ali, M. A.; Shaharyar, M. Oxadiazole mannich bases: Synthesis and antimycobacterial activity. Bioorg. Med. Chem., 2007, 17, 3314-3316.
44. Shaharyar, M. A.; Siddiqui, A.; Ali, M. A. Synthesis and Anti Tuberculostatic Activity of Novel 1,3,4-Oxadiazole Derivatives. J. Chin. Chem. Soc, 2007, 54, 5-8.
45. Vazquez, G. N.; Salinas, G. M. M.; Fajardo, Z. V. D.; Villarreal, J. V.; Soto, S. E.; Salazar, F. G.; Nunez, E. H.; Fernandez, S. S. Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines. Bioorg. Med. Chem., 2007, 15, 5502-5508.
46. Pattan, S. R.; Rabara, P. A.; Pattan, J. S.; Bukitagar, A. A.; Wakale, V. S.; Musmade, D. S. Synthesis and evaluation of some novel substituted 1,3,4-oxadiazole and pyrazole derivatives for antitubercular activity. Ind. J. Chem., 2009, 48B, 1453-1456.
47. Ananthan, S.; Faaleolea, E. R.; Goldman, R. C; Hobrath, J. V.; Kwong, C. D.; Laughon, B. E.; Maddry, J. A.; Mehta, A.; Rasmussen, L.; Reynolds, R. C; Secrist J. A.; Shindo, N.; Showe, D. N.; Sosa, M. I.; Suling, W. J.; White, E. L. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis, 2009, 89, 334-353.
48. Mallikarjuna, B. P.; Sastry, B. S.; Kumar, G. V. S.; Rajendraprasad, Y.; Chandrashekar, S. M.; Sathisha, K. Synthesis of new 4-isopropylthiazole hydrazide analogs and some derived clubbed triazole, oxadiazole ring systems - A novel class of potential antibacterial, antifungal and antitubercular agents. Eur. J. Med. Chem., 2009, 44, 4739-4746.
49. Kumar, G. V. S.; Rajendraprasad, Y.; Mallikarjuna, B. P.; Chandrashekar, S. M.; Kistayya, C. Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1,2,4-triazole and 1,3,4-oxadiazoles as potential antimicrobial and antitubercular agents. Eur. J. Med. Chem., 2010, 45, 2063-2074.
50. Dahlgren, S. E.; Dalhamn, T. The Anti-Inflammatory Action of Phenyl-Methyl-Oxadiazole (PMO): An Experimental Study on the Guinea-Pig Trachea. Acta Pharmacol. Toxicol. 1972, 31, 193-202.
51. Unangst, P. C; Shrum, G. P.; Connor, D. T.; Dyer, R. D.; Schrier, D. J. Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors. J. Med. Chem., 1992, 35, 3691-3698.
52. Nicolaides, D. N.; Fylaktakidou, K.C.; Litinas, K. E.; Litina, D. H. Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives. Eur. J. Med. Chem., 1998, 33, 715-724.
53. Leite, L. F. C. C; Ramos, M. N.; Da Silva, J. B. P.; Miranda, A. L. P.; Fraga, C. A. M.; Barreiro, E. J. Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.
54. Srivastava, R. M.; Lima, A. D. A.; Viana, O. S.; Silva, M. J. D. C; Catanho, M. T. J. A.; De Morais, J. O. F. Antiinflammatory Property of 3-Aryl-5-(n-propyl)-1,2,4-oxadiazoles and Antimicrobial Property of 3-Aryl-5-(n-propyl)-4,5-dihydro-1,2,4-oxadiazoles: Their Syntheses and Spectroscopic Studies. Bioorg. Med. Chem., 2003, 11, 1821-1827.
55. Bezerra, N. M. M.; Oliveira, S. P. D.; Srivastava, R. M.; Silva, J. R. D. Il Farmaco, 2005, 60, 955-960.
56. Wells, M. A. W.; Henninger, T. C; Spano, S. A. F.; Matheis, C. M. M.; Ritchie, D. M.; Argentieri, D. C; Wachter, M. P.; Hlasta, D. J. Bioorg. Med. Chem. Lett., 2004, 14, 4307-4311.
57. Garfunkle, J.; Ezzili, C; Rayl, T. J.; Hochstatter, D. G.; Hwang, I.; Boger, D. L. Optimization of the Central Heterocycle of a-Ketoheterocycle Inhibitors of Fatty Acid Amide Hydrolase. J. Med. Chem., 2008, 51, 4392-4403.
58. Kumar, A.; Rajput, C. S. Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives. Eur. J. Med. Chem., 2009, 44, 83.
59. Akhter, M.; Husain, A.; Azad, B.; Ajmal, M. Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: Synthesis and their antiinflammatory and analgesic activities. Eur. J. Med. Chem., 2009, 44, 2372-2378.
60. Husain, A.; Ajmal, M. Synthesis of novel 1,3,4-oxadiazole derivatives and their biological properties. Acta. Pharm., 2009, 59, 223-233.
61. Narayana, B.; Ashalatha, B. V.; Vijaya Raj, K. K.; Fernandes, J.; Sarojini, B. K. Synthesis of some new biologically active 1,3,4-oxadiazolyl nitroindoles and a modified Fischer indole synthesis of ethyl nitro indole-2-carboxylates. Bioorg. Med. Chem., 2005, 13, 4638-4644.
62. Bhandari, S. V.; Bothara, K. G.; Raut, M. K.; Patil, A. A.; Sarkate, A. P.; Mokale, V. J. Design, Synthesis and Evaluation of Antiinflammatory, Analgesic and Ulcerogenicity studies of Novel S-Substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic Derivatives. Bioorg. Med. Chem., 2008, 16, 1822-1831.
63. Kadi, A. A.; Brollosy, N. R. E.; Deeb, O. A. A.; Habib, E. E.; Ibrahim, T. M.; Emam, A. A. E. Synthesis, antimicrobial, and antiinflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles Eur. J. Med. Chem., 2007, 42, 235-242.
64. Velazquez, C; Rao, P. N. P.; McDonald, R.; Knaus, E. E. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents. Bioorg. Med. Chem., 2005, 13, 2749-2757.
65. Boschelli, D. H.; Connor, D. T.; Bornemeier, D. A.; Dyer, R. D.; Kennedy, J. A.; Kuipers, P. J.; Okonkwo, G. C; Schrier, D. J.; Wright, C. D. 1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities. J. Med. Chem., 1993, 36, 1802-1810.
66. Satyanarayana, K.; Rao, M. N. A. Synthesis of 4-[5-(substituted aryl)-4,5-dihydro-lH-pyrazol-3-yl]-3-phenylsydnonesas antiinflammatory, antiarthritic and analgesic agents Eur. J. Med. Chem., 1995, 30, 641-645.
67. Amir, M.; Javed, S. A.; Kumar, H. Synthesis of some 1,3,4-oxadiazole derivatives as potential anti-inflammatory agents. Indian J. Chem., 2007, 46B, 1014-1019.
68. Wagle, S.; Adhikari, A. V.; Kumari, N. S. Synthesis of some new 2-(3-methyl-7- substituted-2-oxoquinoxalinyl) -5-(aryl)-1,3,4-oxadiazoles as potential non-steroidal anti-inflammatory and analgesic agents. Indian J. Chem., 2008, 47B, 439-448.
69. Breuer, H. Nitroheterocycles. I. Nitrofuryl-substituted 3-amino-1,2,4-oxadiazoles and 5-amino-1,2,4-oxadiazoles. J. Med. Chem., 1969, 12, 708-709.
70. Robinson, C. H.; Bueding, E.; Fisher, J. Relationship between Structure, Conformation, and Antischistosomal Activity of Nitroheterocyclic Compounds. Mol. Pharmacol, 1970, 6, 604-616.
71. Simeonov, A.; Jadhav, A.; Sayed, A. A.; Wang, Y.; Nelson, M. E.; Thomas, C. J.; Inglese, J.; Williams, D. L.; Austin, C. P. Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade. PLoS Negl. Trop. Dis., 2008, 2, e127.
72. Loukas, A.; Bethony, J. M. New drugs for an ancient parasite Nat. Med., 2008, 14, 365-367.
73. Sayed, A. A.; Simeonov, A.; Thomas, C. J.; Inglese, J.; Austin, C. P.; Williams, D. L. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat. Med., 2008, 14, 407-412.
74. Thomas, C. J.; Maloney, J.; Bantukallu, G. R.; Sayed A. A.; Simeonov, A.; Williams, D. L. Oxadiazole-2-oxides as antischistosomal agents. WO 019772, February 18, 2010.
75. Rai, G.; Thomas, C. J.; William, D. L.; Maloney, J. Synthesis of oxadiazole-2-oxide analogues as potential antischistosomal agents. Tetrahedron Lett., 2009, 50, 1710-1713.
76. Ainsworth, C.; Buting, W. E.; Callender, M. E.; McCowen, M. C. Anthelmintic activity of 1,2,4-oxadiazoles. J. Med. Chem., 1967, 10, 208-211.
77. Narayanan, V. L.; Haugwitz, R. D. Anthelmintic 5-(Pyridyl)-3-(isothiocyanophenyl) oxadiazoles. U. S. Patent 3, 853,893, December 10, 1974.
78. Naganagowda, G.; Padmashali, B. Synthesis, antimicrobial, and anthelmintic activities of some new 3-chlorobenzothiophene-2-carbonylchloride derivatives. Phosphorus, Sulfur Silicon Relat. Elem., 2010, 185, 1691-1700.
79. Khan, M. T. H.; Choudhary, M. I.; Khan, K. M.; Ranib, M.; Rahman, A. Structure-activity relationships of tyrosinase inhibitory combinatorial library of 2,5-disubstituted-1,3,4-oxadiazole analogues. Bioorg. Med. Chem., 2005, 13, 3385-3395.
80. Sawant, R.; Lanke, P.; Jadhav, G.; Bhangale, L. QSAR analysis of structurally similar 1, 3, 4-oxadiazoles as enzyme tyrosinase inhibitors. Drug Invention Today, 2010, 2(2), 169-172.
81. Ghani, U.; Ullah, N. New potent inhibitors of tyrosinase: Novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site. Bioorg. Med. Chem., 2010, 18, 4042-4048.
82. Lam, K. W.; Syahida, A.; Ul-Haq, Z.; Rahman, M. B. A.; Lajis, N. H. Synthesis and biological activity of oxadiazole and triazolothiadiazole derivatives as tyrosinase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 3755-3759.
83. Zablocki, J.; Kalla, R.; Perry, T.; Palle, V.; Varkhedkar, V.; Xiao, D.; Piscopio, A.; Maa, T.; Gimbel, A.; Hao, J.; Chu, N.; Leung, K.; Zeng, D. The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg. Med. Chem. Lett., 2005, 15, 609-612.
84. Elzein, E.; Kalla, R.; Li, X.; Perry, T.; Parkhill, E.; Palle, V.; Varkhedkar, V.; Gimbel, A.; Zeng, D.; Lustig, D.; Leung, K.; Zablocki, J. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists Bioorg. Med. Chem. Lett., 2006, 16, 302-306.
85. Mitchell, C. J.; Ballantine, S. P.; Coe, D. M.; Cook, C. M.; Delves, C. J.; Dowle, M. D.; Edlin, C. D.; Hamblin, J. N.; Holman, S.; Johnson, M. R.; Jones, P. S.; Keeling, S. E.; Kranz, M.; Lindvall, M.; Lucas, F. S.; Neu, M.; Solanke, Y. E.; Somers, D. O.; Trivedi, N. A.; Wiseman, J. O. Pyrazolopyridines as potent PDE4 inhibitors: 5-Heterocycle SAR. Bioorg. Med. Chem. Lett., 2010, 20, 5803-5806.
86. Biagini, P.; Biancalani, C.; Graziano, A.; Cesari, N.; Giovannoni, M. P.; Cilibrizzi, A.; Piaz, V. D.; Vergelli, C.; Crocetti, L.; Delcanale, M.; Armani, E.; Rizzi, A.; Puccini, P.; Gallo, P. M.; Spinabelli, D.; Caruso, P. Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity. Bioorg. Med. Chem., 2010, 18, 3506-3517.
87. Macdonald, D.; Mastracchio, A.; Perrier, H.; Dubé, D.; Michel Gallant, Patrick Lacombe, Denis Deschenes, Bruno Roy, John Scheigetz, Bateman, K.; Li, C.; Trimble, L. A.; Day, S.; Chauret, N.; Griffith, D. A. N. S.; Huang, Z.; Laliberté, F.; Liu, S.; Ethier, D.; Pon, D.; Muise, E.; Boulet, L.; Chan, C. C.; Styhler, A.; Charleson, S.; Mancini, J.; Masson, P.; Claveau, D.; Nicholson, D.; Turner, M.; Young, R. N.; Girard, Y. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Bioorg. Med. Chem. Lett., 2005, 15, 5241-5246.
88. Guay, D.; Boulet, L.; Friesen, R. W.; Girard, M.; Hamel, P.; Huang, Z.; Laliberté, F.; Laliberté, S.; Mancini, J A.; Muise, E.; Pon, D.; Styhler, A. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: Identification of MK-0873, a potent and effective PDE4 inhibitor. Bioorg. Med. Chem. Lett., 2008, 18, 5554-5558.
89. Palmer, J. T.; Rydzewski, R. M.; Mendonca, R. V.; Sperandio, D.; Spencer, J. R.; Hirschbein, B. L.; Lohman, J.; Beltman, J.; Nguyen, M.; Liu, L. Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 3434-3439.
90. Xu, J.; Wei, L. R.; Mathvink, J.; Edmondson, S. D.; Eiermann, G. J.; He, H.; Leone, J. F.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Patel, S. B.; Petrov, A.; Scapin, G.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5373-5377.
91. Nordhoff, S.; Bulat, S.; Gálvez, S. C; Hill, O.; Enger, B. H.; Canet, M. L.; Rosenbaum, C; Rummey, C; Thiemann, M.; Matassa, V. G.; Edwards, P. J.; Feurer, A. The design of potent and selective inhibitors of DPP-4: Optimization of ADME properties by amide replacements. Bioorg. Med. Chem. Lett., 2009, 19, 6340-6345.
92. Xu, J.; Wei, L.; Mathvink, R.; He, J.; Park, Y. J.; He, H.; Leiting, B.; Lyons, K. A.; Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 2533-2536.
93. Barth, F.; Congy, C; Gueule, P.; Carmona, M. R.; Broeck, D. V. (1,5-Diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, preparation method thereof and use of same in therapeutics. U. S. Patent 7,632,852 B2, December 15, 2009.
94. Lee, C. S.; Koo, K. D.; Koh, J. S.; Kim, S.; Kim, D. M.; Kim, M. J.; Kim, B.; Yoon, S. K.; Kim, S.; Yim, H. J.; Hur, G. C; Lee, S. H.; Han, H. O.; Kim, K. H.; Kim, G.; Kwon, O.; Kwon, T.; Lee, H. B.; Chung, H.; Kim, M.; Lim, D.; Kim, Y.; Kim, S. Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent WO 037828 A1, April 28, 2005.
95. Shingalapur, R. V.; Hosamani, K. M.; Keri, R. S.; Hugar, M. H. Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studies. Eur. J. Med. Chem., 2010, 45, 1753-1759.
96. Husain, M. I.; Kumar, A.; Srivastava, R. C. Synthesis of N-(2- naphthyloxyacetyl)-thiosemicarbazides and 2-arylamino-5-(2- naphthyloxymethyl)-1,3,4-thiadiazoles/oxadiazoles as oral hypoglycemic agents. Curr. Sci., 1986, 55(14), 644-646.
97. Liu, K. G.; Smith, J. S.; Ayscue, A. H.; Henke, B. R.; Lambert, M. H.; Leesnitzer, L. M.; Plunket, K. D.; Willson, T. M.; Sternbach, D. D. Identification of a Series of Oxadiazole-Substituted a-Isopropoxy Phenylpropanoic Acids with Activity on PPARa, PPARP, and PPARy Bioorg. Med. Chem. Lett., 2001, 11, 2385-2388.
98. Soni, L. K.; Gupta, A. K.; Kaskhedikar, S. G. 2D-QSAR Analysis of Oxadiazole Substituted a-Isopropoxy phenylpropionic Acids as PPAR-a & PPAR-y Agonists. E. J. Chem., 2004, 1(2), 170-177.
99. Diana, G. D.; Volkots, D. L.; Nitz, T. J.; Biailly, T. R.; Long, M. A.; Vesico, N.; Aldous, A.; Pevear, D. C; Dukto, F. J. Oxadiazoles as Ester Bioisosteric Replacements in Compounds Related to Disoxaril. Antirhinovirus Activity. J. Med. Chem., 1994, 37, 2421-2436.
100. Tan, T. M. C. Chen, Y.; Kong, K. H.; Bai, J.; Li, Y.; Lim, S. G.; Ang, T. H.; Lama, Y. Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents. Antiviral Res., 2006, 71, 7-14.
101. Grinsztejn, B.; Nguyen, B. Y.; Katlama, C; Gatell, J. M.; Lazzarin, A.; Vittecoq, D.; Gonzalez, C. J.; Chen, J.; Harvey, C. M.; Isaacs, R. D. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, 2007, 369, 1261-1269.
102. Mouscadeta, J. F.; Delelis, O.; Marcelin, A. G.; Tchertanov, L. Resistance to HIV-1 integrase inhibitors: A structural perspective. Drug Resist. Update., 2010, 13, 139-150.
103. Veerasamy, R.; Sivadasan, S.; Karupiah, S.; Dhanaraj, S. A. QSAR study of substituted 1,3,4-oxadiazole naphthyridines as HIV-1 integrase inhibitors. Eur. J. Med. Chem., 2010, 45, 2791-2797.
104. Kim, R. M.; Rouse, E. A.; Chapman, K. T.; Schleif, W. A.; Olsen, D. B.; Stahlhut, M.; Rutkowski, C. A.; Eminib, E. A.; Tata, J. R. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1. Bioorg. Med. Chem. Lett., 2004, 14, 4651-4654.
105. Leung, C. S.; Zeevaart, J. G.; Domaoal, R. A.; Bollini, M.; Thakur, V. V.; Spasov, K. A.; Anderson, K. S.; Jorgensen, W. L. Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. Bioorg. Med. Chem. Lett., 2010, 20, 2485-2488.
106. Sakamoto, T.; Cullen, M. D.; Hartman, T. L.; Watson, K. M.; Buckheit, R. W.; Pannecouque, C.; Clercq, E. D.; Cushman, M. Synthesis and Anti-HIV Activity of New Metabolically Stable Alkenyldiarylmethane Non-Nucleoside Reverse Transcriptase Inhibitors Incorporating N-Methoxy Imidoyl Halide and 1,2,4-Oxadiazole Systems. J. Med. Chem., 2007, 50, 3314-3321.
107. Adelstein, G. W.; Yen, Ch. H.; Dajani, E. Z.; Bianchi, R. G. 3,3-Diphenyl-3-(2-alkyl-l,3,4-oxadiazol-5-yl)propylcycloalkylaminaes, a Novel Series of Antidiarrheal Agents. J. Med. Chem., 1976, 19, 1221-1225.
108. Almasirad, A.; Tabatabai, S. A.; Faizi, M.; Kebriaeezadeh, A.; Mehrabi, N.; Dalvandia, A.; Shafieea, A. Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2-fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles. Bioorg. Med. Chem. Lett., 2004, 14, 6057-6059.
109. Zarghi, A.; Hamedi, S.; Tootooni, F.; Amini, B.; Sharift, B.; Faizi, M.; Tabatabai, S. A. Shafiee, A. Synthesis and Pharmacological Evaluation of New 2-Substituted-5-{2-[(2-halobenzyl)thio)phenyl}-1,3,4-oxadiazoles as Anticonvulsant Agents. Sci. Pharm., 2008, 76, 185-201.
110. Yar, M. S.; Akhter, M. W. Synthesis and anticonvulsant activity of substituted oxadiazole and thiadiazole derivatives. Acta Pol. Pharm. Drug Res., 2009, 66(4), 393-397.
111. Lankau, H. J.; Unverferth, K.; Grunwald, C.; Hartenhauer, H.; Heinecke, K.; Bernöster, K.; Dost, R.; Egerland, U.; Rundfeldt, C. New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity. Eur. J. Med. Chem., 2007, 42, 873-879.
112. Kumar, D.; Sundaree, S.; Johnson, E. O.; Shah, K. An efficient synthesis and biological study of novel indolyl-1,3,4-oxadiazoles as potent anticancer agents. Bioorg. Med. Chem. Lett., 2009, 19, 4492-4494.
113. Zaied, M. A. A.; Telbani, E. M. E.; Elgemeie, G. H.; Nawwar, G. A. M. Synthesis and in vitro antitumor activity of new oxadiazole thioglycosides. Eur. J. Med. Chem., 2011, 46, 229-232.
114. Han, D.; Menga, X. B.; Wang, L. N.; Liu, H.; Yao, Y.; Wanga, Z.; Yang, Z. J.; Liu, Z. M.; Li, Z. J. Efficient synthesis of a series of novel fructose-based 3-acetyl-5-alkyl-2,3-dihydro-1,3,4-oxadiazole derivatives and studies of the reaction mechanism. Tetrahedron: Asymmetry, 2009, 20, 399-410.
115. Li, W. S.; More, S. V.; Chie-Hong Wang, Ya Ching Jen, Ching-Fa Yao, Tein-Fu Wang, Chin-Chun Hung, Shu-Chuan Jao Synthesis and structure-activity relationships of novel furazan-3,4-diamide analogs as potent anti-cancer agents. Bioorg. Med. Chem. Lett., 2010, 20, 1148-1152.
116. Koufaki, M.; Kiziridi, C.; Nikoloudaki, F.; Alexis, M. N. Design and synthesis of 1,2-dithiolane derivatives and evaluation of their neuroprotective activity. Bioorg. Med. Chem. Lett., 2007, 17, 4223-4227.
117. Koufaki, M.; Kiziridi, C.; Alexi, X.; Alexis, M. N. Design and synthesis of novel neuroprotective 1,2-dithiolane/chroman hybrids. Bioorg. Med. Chem., 2009, 17, 6432-6441.
118. Koufaki, M.; Theodorou, E.; Alexi, X.; Alexis, M. N. Synthesis of a second generation chroman/catechol hybrids and evaluation of their activity in protecting neuronal cells from oxidative stress-induced cell death. Bioorg. Med. Chem., 2010, 18, 3898-3909.
119. Tiwari, S. B.; Kohli, D. V. Synthesis of 3-(5-bromo-2,3-dimethoxy-phenyl)-[1, 2, 4]oxadiazole analogues and their evaluation as anti-Parkinsons agents. Med. Chem. Res., 2008, 17, 386-398.
120. Anette Graven Sams, Gitte Kobberøe Mikkelsen, Mogens Larsen, Lars Torup, Lise Tøttrup Brennum, Tenna Juul Schrøder, Benny Bang-Andersen. Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorg. Med. Chem. Lett., 2010, 20, 5241-5244.
121. Hong Zhu, Mary B. Young, Philippe G. Nantermet, Samuel L. Graham, Dennis Colussi, Ming-Tain Lai, Beth Pietrak, Eric A. Price, Sethu Sankaranarayanan, Xiao-ping Shi, Katherine Tugusheva, Marie A. Holahan, Maria S. Michener, Jacquelynn J. Cook, Adam Simon, Daria J. Hazuda, Joseph P. Vacca, Hemaka A. Rajapakse. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 1779-1782.
122. Ono, M.; Haratake, M.; Saji, H.; Nakayama, M. Development of novel b-amyloid probes based on 3,5-diphenyl-1,2,4-oxadiazole. Bioorg. Med. Chem., 2008, 16, 6867-6872.
123. Watanabe, H.; Ono, M.; Ikeoka, R.; Haratake, M.; Saji, H.; Nakayama, M. Synthesis and biological evaluation of radioiodinated 2,5-diphenyl-1,3,4-oxadiazoles for detecting b-amyloid plaques in the brain. Bioorg. Med. Chem., 2009, 17, 6402-6406.
124. Huhtiniemi, T.; Suuronen, T.; Rinne, V. M.; Wittekindt, C.; Kakkonen, M. L.; Jarho, E.; Wallén, E. A. A.; Salminen, A.; Poso, A.; Leppänen, J. Sirtuins have pathogenetic roles in cancer, diabetes, heart failure, neurodegeneration, and aging, and they are currently under investigation as new potential targets for drug discovery. J. Med. Chem., 2008, 51, 4377-4380.
125. Adelstein, G. W. Antiarrhythmic Agents. Synthesis and Biological Activity of Some Tetrazole and Oxadiazole Analogs of 4-Dialkylamino-2,2 diarylbutyramides. J. Med. Chem., 1973, 16, 309-312.
126. Schlecker, R.; Thieme, P. C. The synthesis of antihypertensive 3-(1,3,4-oxadiazol-2-yl)phenoxypropanolahines. Tetrahedron, 1988, 44, 3289-3294.
127. Meyer, E.; Joussef, A. C.; Souza, L. D. B. P. D. Synthesis of New 1,2,4- and 1,3,4-Oxadiazole Derivatives as Potential Nonpeptide Angiotensin II Receptor Antagonists. Synth. Comm., 2006, 36, 729-741.
128. Meyer, E.; Joussef, A. C.; Gallardo, H. Synthesis of new 1,2,4- and 1,3,4-oxadiazole derivatives. Synthesis, 2003, 6, 899-905.
129. Partyka, R. A.; Crenshaw, R. R. 1,3,4-Oxadiazole amides. U. S. Patent 4,001,238, January 4, 1977.
130. Murthy, K. S. K.; Weeratunga, G.; Zhou, T.; Guntoori, B. R. Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tidazosin and related antihypertensive medicines. U. S. Patent 5,919,931 July 6, 1999.
131. Nichols, P. L.; Brand, J.; Briggs, M.; D'Angeli, M.; Farge, J.; Garland, S. L.; Goldsmith, P.; Hutchings, R.; Kilford, I.; Li, H. Y.; MacPherson, D.; Nimmo, F.; Sanderson, F. D.; Sehmi, S.; Shuker, N.; Skidmore, J.; Stott, M.; Sweeting, J.; Tajuddin, H.; Takle, A. K.; Trani, G.; Wall, I. D.; Ward, R.; Wilson, D. M.; Witty, D. Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine. Bioorg. Med. Chem. Lett., 2010, 20, 1368-1372.
132. Fisher, A.; Brandeis, R.; Bar-Ner, R. H.; Kliger-Spatz, M.; Natan, N.; Sonego, H.; Marcovitch, I.; Pittel, Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J. Mol Neurosci. 2002, 19, 145-153.
133. Saunders, J.; Cassidy, M.; Freedman, S. B.; Harley, E. A.; Iversen, L. L.; Kneen, C.; MacLeod, A. M.; Merchant, K. J.; Snow, R. J.; Baker, R. Novel Quinuclidine-Based Ligands for the Muscarinic Cholinergic Receptor J. Med. Chem., 1990, 33, 1128-1138.
134. Orlek, B. S.; Blaney, F. E.; Brown, F.; Clark, M. S. G.; Hadley, M. S.; Hatcher, J.; Riley, G. J.; Rosenberg, H. E.; Wadsworth, H. J.; Wyman, P. Comparison of Azabicyclic Esters and Oxadiazoles as Ligands for the Muscarinic Receptor J. Med. Chem., 1991, 34, 2726-2735.
135. Messer, W. S. Jr.; Abuh, Y. F.; Liu, Y.; Periyasamy, S.; Ngur, D. O.; Edgar, M. A. N.; El-Assadi, A. A.; Sbeih, S.; Dunbar, P. G.; Roknich, S.; Rho, T.; Fang, Z.; Ojo, B.; Zhang, H.; Huzl, III J. J.; Nagy P. I. Synthesis and Biological Characterization of 1,4,5,6-Tetrahydropyrimidine and 2-Amino-3,4,5,6-tetrahydropyridine Derivatives as Selective m1 Agonists. J. Med. Chem., 1997, 40, 1230-1246.
136. Harfenist M, Heuser DJ, Joyner CT, Batchelor JF and White HL. Selective inhibitors of monoamine oxidase. Structure activity relationship of tricyclics bearing imidazoline, oxadiazole or tetrazole groups. J. Med. Chem., 1996, 39, 1857-1863.
137. Ke, S.; Li, Z.; Qian, X. 1,3,4-Oxadiazole-3(2H)-carboxamide derivatives as potential novel class of monoamine oxidase (MAO) inhibitors: Synthesis, evaluation, and role of urea moiety. Bioorg. Med. Chem., 2008, 16, 7565-7572.
138. Amtul, Z.; Rasheed, M.; Choudhary, M. I.; Rosanna, S.; Khan, K. M.; Rahman, A.-ur. Kinetics of novel competitive inhibitors of urease enzymes by a focused library of oxadiazoles/thiadiazoles and triazoles. Biochem. Biophy. Res. Comm., 2004, 319, 1053-1063.
139. Vu, C. B.; Corpuz, E. G.; Pradeepan, S. G.; Violette, S.; Bartlett, C.; Sawyer, T. K. Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70. Bioorg. Med. Chem. Lett., 1999, 9, 3009-3014.
140. Vu, C. B.; Corpuz, E. G.; Merry, T. J.; Pradeepan, S. G.; Bartlett, C.; Bohacek, R. S.; Botfield, M. C.; Eyermann, C. J.; Lynch, B. A.; MacNeil, I. A.; Ram, M. K.; van Schravendijk, M. R.; Violette, S.; Sawyer, T. K. Discovery of Potent and Selective SH2 Inhibitors of the Tyrosine Kinase ZAP-70. J. Med. Chem., 1999, 42, 4088-4098.
141. Yan, L.; Huo, P.; Doherty, G.; Toth, L.; Hale, J. J.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei, G.-J.; Chrebet, G.; Bergstrom, J.; Card, D.; Quackenbush, E.; Wickham, A.; Mandala, S. M. Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes. Bioorg. Med. Chem. Lett., 2006, 16, 3679-3683.
142. Yan, L.; Huo, P.; Hale, J. J.; Mills, S. G.; Hajdu, R.; Keohane, C. A.; Rosenbach, M. J.; Milligan, J. A.; Shei, G.-J.; Chrebet, G.; Bergstrom, J.; Card, D.; Mandala, S. M. SAR studies of 3-arylpropionic acids as potent and selective agonists of sphingosine-1-phosphate receptor-1 (S1P1) with enhanced pharmacokinetic properties. Bioorg. Med. Chem. Lett., 2007, 17, 828-831.